Interference of BCR-ABL1 kinase activity with antigen receptor signaling in B cell precursor leukemia cells

被引:0
|
作者
Klein, F [1 ]
Feldhahn, N [1 ]
Müschen, M [1 ]
机构
[1] Univ Dusseldorf, Lab Mol Stem Cell Biol, ITZ, Inst Transplantat Diagnost & Cell Therapeut, D-40225 Dusseldorf, Germany
关键词
antigen receptor; B cell precursor leukemia; BCR-ABL1; STI571;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The chromosomal translocation t,(9;22) resulting in the fusion of the BCR and ABL1 genes, represents a recurrent aberration in B cell precursor leukemia cells. Their normal counterparts, B cell precursor cells, are positively selected for survival signals through the antigen receptor, whose expression requires a functional immunoglobulin heavy chain (IGH) gene rearrangement. Unexpectedly, B cell precursor leukemia cells harboring a BCR-ABL1 gene rearrangement do not depend on antigen receptor mediated survival signals. Genes involved in the signaling cascade of the antigen receptor are silenced and in most cases, the dominant tumor clone does not carry a functional IGH gene rearrangement. However, upon inhibition of the BCR-ABL1 kinase activity by STI571, only leukemia cells expressing an antigen receptor are able to survive. Since resistance to STI571 is frequent in the therapy of BCR-ABL1(+) B cell precursor leukemia, antigen receptor signaling may represent a mechanism through which these cells can temporarily evade STI571-induced apoptosis. This may open a time frame, during which leukemia cells acquire secondary transforming events that confer definitive resistance to STI571.
引用
收藏
页码:858 / 860
页数:3
相关论文
共 50 条
  • [31] Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1
    Amparo Pimentel-Villar, M.
    Morales-Camacho, Rosario M.
    Teresa Vargas, M.
    Jimenez-Jambrina, Margarita
    Martin-Chacon, Eusebio
    Prats-Martin, Concepcion
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (01) : 7 - 7
  • [32] TARGETING THE HEDGEHOG SIGNALING PATHWAY IN THERAPY-RESISTANT BCR-ABL1 POSITIVE LEUKEMIA
    Tauchi, T.
    Katagiri, S.
    Kimura, S.
    Maekawa, T.
    Ohyashiki, K.
    HAEMATOLOGICA, 2012, 97 : 207 - 207
  • [33] Reversibility of acute B-cell leukaemia induced by BCR-ABL1
    Huettner, CS
    Zhang, P
    Van Etten, RA
    Tenen, DG
    NATURE GENETICS, 2000, 24 (01) : 57 - 60
  • [34] Retrospective analysis of toxicities and clinical outcomes with BCR-ABL1 tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.
    Venn, Chad Michael
    Zacholski, Kyle
    Tran, Valerie
    Alnimer, Yanal Mufeed
    Ho, Thuy
    Maher, Keri Renee
    Bouligny, Ian Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia
    Buzzatti, Elisa
    Forghieri, Fabio
    Paterno, Giovangiacinto
    Marchesi, Francesco
    Sarlo, Chiara
    Giglio, Fabio
    Fracchiolla, Nicola
    Sciume, Mariarita
    Palmieri, Raffaele
    Esposito, Fabiana
    Guarnera, Luca
    Mercante, Lisa
    Pascale, Maria Rosaria
    Mallegni, Flavia
    Savi, Arianna
    Forte, Vittorio
    Maurillo, Luca
    Buccisano, Francesco
    Venditti, Adriano
    Del Principe, Maria Ilaria
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (07)
  • [36] TARGETING THE DOPAMINE RECEPTOR SIGNALING REDUCES THE POLYCOMB PROTEIN BMI1 AND LIMITS THE SELF-RENEWAL OF BCR-ABL1 POSITIVE LEUKEMIA CELLS
    Tauchi, T.
    Okabe, S.
    Katagiri, S.
    Ohyashiki, K.
    HAEMATOLOGICA, 2014, 99 : 271 - 271
  • [37] Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
    Pinilla-Ibarz, Javier
    Sweet, Kendra
    Emole, Josephine
    Fradley, Michael
    ANTICANCER RESEARCH, 2015, 35 (12) : 6355 - 6364
  • [38] Secondary fusions as a mechanism of BCR-ABL1 kinase-independent resistance in chronic myeloid leukemia
    Barnes, Evan J.
    Eide, Christopher A.
    Bottomly, Daniel
    Wilmot, Beth
    McWeeney, Shannon K.
    Tognon, Cristina E.
    Druker, Brian J.
    CANCER RESEARCH, 2021, 81 (13)
  • [39] BCR-ABL1 like B-Acute Lymphoblastic Leukemia/Lymphoma A Comprehensive Review
    Jain, Sarika
    Abraham, Anu
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2020, 144 (02) : 150 - 155
  • [40] BCL6 enables Ph plus acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition
    Duy, Cihangir
    Hurtz, Christian
    Koeffler, Phillip H.
    Melnick, Ari M.
    Muschen, Markus
    CANCER RESEARCH, 2011, 71